Health Condition 1: D352- Benign neoplasm of pituitary gland
Conditions
Interventions
Intervention1: OFA Group: Dexmedetomidine (6 mcg/ml) Bolus (1 g/kg) over 10 mins followed by maintenance infusion (0.3 0.7 g/kg/h) till tumor excision : Adjust Concentration
6 mL/hr for all patien
Sponsors
Abhishek kumar
Eligibility
Inclusion criteria
Inclusion criteria: ASA I and II patients undergoing elective TNTS pituitary tumor resection Age 18 to 65 years BMI 18 to 30 kg per meter square
Exclusion criteria
Exclusion criteria: 1. Age less than 18 years or more than 65 years 2. ASA Physical Status IV or above 3. Known allergy or hypersensitivity to any study drugs (e.g., ketamine, lidocaine, dexmedetomidine, fentanyl, propofol, etc.) 4. Patients with pre-existing severe cardiac disease (e.g., unstable angina, recent MI, EF less than 35 percent, Bradyarrythmias, Tachyarrythmias) 5. Patients with significant hepatic or renal dysfunction (LFTs more than 3 normal, serum creatinine more than 2.0 mg/dL) 6. History of chronic opioid use or opioid dependence 7. Preoperative altered mental status (GCS less than 15) 8. Presence of neurological deficits precluding accurate postoperative assessment 9. Patients on antipsychotic or sedative medications 10. Known history of seizure disorder or psychiatric illness 11. Pregnant or lactating women 12. Patients with BMI more than 35 kg/m 13. Refusal to provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| There is no significant difference in intraoperative blood loss or postoperative recovery profile between opioid-free and opioid-based anaesthesia in TNTS surgery. or Opioid-free anaesthesia results in reduced intraoperative blood loss and improved recovery profile compared to opioid-based anaesthesia in TNTS surgery. Timepoint: 4hrs and 6 hrs and 12 hrs | — |
Secondary
| Measure | Time frame |
|---|---|
| NilTimepoint: Nil | — |
Countries
India
Contacts
Public ContactAjit Bhardwaj
Armed Forces Medical College,Pune
Outcome results
None listed